Back

Discontinuation and re-initiation of mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Treating heart failure with diabetes and renal disease Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Ms Laura Landucci

Karolinska University Hospital, Stockholm (Sweden)

6 More presentations in this session

Presentation thumbnail
Pharmacological treatment patterns and outcomes according to the coexistence of heart failure and type 2 diabetes. Data from the Swedish Heart Failure Registry and National Diabetes Registry
Doctor F. Musella (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Insulin therapy in patients with heart failure and type 2 diabetes: predictors of use and associations with outcomes. Data from the Swedish Heart Failure Registry and National Diabetes Registry.
Mr M. Biber (Trieste, IT)
Abstract Slides Video
Presentation thumbnail
Deciphering mortality risk of antidiabetic medications in well-treated heart failure patients with diabetes mellitus
Assistant Professor I. Colluoglu (Karabuk, TR)
Abstract Slides Video
Presentation thumbnail
Survival analysis in heart failure and end-stage chronic kidney disease: a propensity score matched study comparing peritoneal dialysis and hemodialysis
Assistant Professor A. Sahin (Canakkale, TR)
Abstract Slides Video
Presentation thumbnail
Hyperkalemia consequences on the probability of interrupting or lowering renin-angiotensin-aldosterone system inhibitors and risk of hospitalization in patients with chronic cardiovascular conditions
Doctor S. Jimenez-Marrero (Barcelona, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Treating heart failure with diabetes and renal disease
Video

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources